Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe

Abstract

SUMMARY BackgroundThere is little up-to-date review evidence on the prevalence of Helicobacter pylori across Europe. AimTo establish regional and national patterns in H. pylori prevalence across Europe. Secondly, to establish trends over time in H. pylori prevalence and gastric cancer incidence and, thirdly, to report on the relationship between H. pylori prevalence and age group across Europe. MethodsA review of H. pylori prevalence from unselected surveys of adult or general populations across 35 European countries and four European regions since 1990. Secondly, an analysis of trends over time in H. pylori prevalence and in gastric cancer incidence from cancer registry data.

Prevalence and predictors of Helicobacter pylori infection among patients attending a healthcare facility in North-Central Nigeria

“…pylori [12]. However, the prevalence of this present study is lower than report from Ghana which recorded a prevalence of 75.4% among dyspeptic patients [4], reports from Saudi Arabia and Kuwait showing the prevalences of 68% and 62%, respectively [14,15].…”

Updated incidence trends in cardia and non-cardia gastric adenocarcinoma in Sweden

“…Yet, most studies assessing the incidence from earlier periods have found similar results as in the present study, i.e., a stable incidence in gastric cardia cancer, whereas the incidence of non-cardia gastric cancer has declined [11][12][13][14]. A recent comprehensive review of European countries showed a mean annual reduction in the incidence of gastric cancer of 2.1% in Europe from 1993 to 2007 with little variation between countries [15]. Globally, a study using data from Cancer Incidence in five continents from 2003 to 2007 reported an annual decrease of approximately 3% in Europe, Japan and Korea and 2% in North and Latin America [14].…”

Helicobacter pylori Gastritis: Susceptible to Further Testing?

“…Other studies described a prevalence rate of 30-40 % in US adults and a 60-70 % infection rates in immigrant populations and those of lower socioeconomic status and living under crowded circumstances [3,4]. Resistance to clarithromycin, one of the components of recommended first-line therapy, has been increasing, with 10-15 % resistance in 2004 [5] and *30 % resistance reported in the article by Park et al [6] in this issue of Digestive Diseases and Sciences.…”